

Supplementary material has been published as submitted. It has not been copyedited, or typeset by Acta Oncologica

Supplementary table 1a. Population-based breast cancer screening in Iceland, 1990-2020:
– quality indicators among women aged 45-49 and 40-44 years

Quality indicators	<i>Subgroups of age 40-49</i>		p-value
	Age 45-49	Age 40-44	
Attendance, no, %	94792 (60.2)	88904 (60.4)	0.484
<i>Prevalent screen</i>	46175 (49.3)	8042 (9.0)	< 0.001
<i>Subsequent screens</i>	48077 (50.7)	80862 (91.0)	< 0.001
Age at screening, mean (SD)	47,0 (1.4)	41.9 (1.5)	
Recall rate, no. (%)			
All screens	4222 (4.7)	4771 (5.0)	0.007
<i>Prevalent screen</i>	640 (8.0)	2875 (6.2)	< 0.001
<i>Subsequent screens</i>	3582 (4.4)	1896 (3.9)	< 0.001
PPV-1, no. (%)			
All screens	237 (5.6)	138 (2.9)	< 0.001
<i>Prevalent screen</i>	47 (7.3)	76 (2.6)	< 0.001
<i>Subsequent screens</i>	190 (5.3)	62 (3.3)	0.001
Rate of screen detected-cancer, per 1000			
All screens	2.8	1.5	< 0.001
<i>Prevalent screen</i>	6.1	1.7	< 0.001
<i>Subsequent screens</i>	2.5	1.4	< 0.001
Rate of interval cancer, per 1000			
All screens	2.0	1.6	0.089
<i>Prevalent screen</i>	2.4	1.6	0.100
<i>Subsequent screens</i>	1.9	1.6	0.282

Supplementary table 1b. Tumour characteristics among women aged 40–44 and 40–49 with screen-detected, interval, and clinically diagnosed invasive breast cancers, 1990–2020

Tumour characteristics	Screen-detected breast cancers			Interval breast cancers			Clinically diagnosed breast cancers		
	<i>Age 45-49</i>	<i>Age 40-44</i>	p-value	<i>Age 45-49</i>	<i>Age 40-44</i>	p-value	<i>Age 45-49</i>	<i>Age 40-44</i>	p-value
All tumours, no	248	146		173	152		192	166	
Type (%)									
In situ	47 (19.0)	29 (19.9)	0.825	11 (6.4)	17 (11.2)	0.122	5 (2.6)	10 (6.0)	0.080
Invasive**	201 (81.0)	117 (80.1)		162 (93.6)	135 (88.8)		187 (97.4)	156 (94.0)	
Tumour diameter, mm									
Median	15.0	15.5	0.675	18.0	20.0	0.675	20.0	21.0	0.512
Mean	18.2	19.1	0.593	23.1	22.5	0.814	27.9	26.3	0.722
All <10 (%)	56 (28.0)	34 (30.4)	0.699	27 (17.3)	19 (15.1)	0.615	26 (15.0)	19 (13.4)	0.677
<i>Prevalent screen</i>	9 (24.3)	16 (26.2)	0.834						
<i>Subsequent screens</i>	47 (29.1)	18 (35.3)	0.410						
All 10 ≥, <21, n (%)	86 (43.4)	42 (37.5)	0.308	64 (41.0)	49 (38.9)	0.716	63 (36.4)	50 (35.2)	0.824
<i>Prevalent screen</i>	15 (40.5)	24 (39.3)	0.907						
<i>Subsequent screens</i>	71 (44.1)	18 (35.3)	0.267						
All >20, n (%)	56 (28.3)	36 (32.1)	0.475	65 (41.7)	58 (46.0)	0.462	84 (48.6)	73 (51.4)	0.614
<i>Prevalent screens</i>	13 (35.1)	21 (34.4)	0.943						
<i>Subsequent screen</i>	43 (26.7)	15 (29.4)	0.706						
Positive node status, n (%)									
All	77 (39.1)	50 (45.0)	0.308	84 (53.8)	68 (54.8)	0.869	81 (46.8)	62 (45.3)	0.784
<i>Prevalent screen</i>	16 (43.2)	29 (47.5)	0.060						
<i>Subsequent screens</i>	61 (38.1)	21 (42.0)	0.010						
ER, n (%)									
Positive	165 (85.5)	85 (79.4)	0.531	113 (72.9)	87 (68.5)	0.574	126 (71.6)	103 (72.5)	0.846
HER2, n (%) ***									
Positive	8 (22.6)	8 (11.3)	0.474	20 (21.3)	8 (11.0)	0.077	19 (3.7)	14 (2.7)	0.273